Related Experiment Video
Updated: Jul 17, 2025

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
General practitioner management of comorbid insomnia and sleep apnoea
Alexander Sweetman1, Oliver Frank2, Nigel Stocks3
1PhD, Research Associate, Adelaide Institute for Sleep Health (AISH): A Centre of Research Excellence, College of Medicine and Public Health, Flinders University, SA; Research Associate, National Centre for Sleep Health Services Research (NCSHSR): An NHMRC Centre of Research Excellence, Flinders University, SA.
Background:
Insomnia and obstructive sleep apnoea are the two most common sleep disorders and frequently co-exist. Patients with comorbid insomnia and sleep apnoea experience worse daytime function, mental health and physical health than patients with either disorder alone. General practitioners may face unique challenges in the assessment and management of this prevalent and debilitating condition.
Objective:
This article aims to provide an overview of the prevalence, consequences, assessment and management of patients with comorbid insomnia and sleep apnoea in Australian general practice.
Discussion:
Patients with either insomnia or sleep apnoea should be assessed for both conditions. Treatments for both disorders should be offered to patients with both conditions. The recommended treatment for insomnia is cognitive behavioural therapy, whereas the recommended first-line treatment for moderate and severe obstructive sleep apnoea is lifestyle/weight management advice (where relevant) and continuous positive airway pressure therapy.
More Related Videos
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Management of Insomnia
Insomnia
Multiple factors contribute...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
CNS Depressants: Barbiturates and Benzodiazepines
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

